for this Overall with gedatolisib with robust study made HR+/HERX- track. significant breast Phase remains and our your appreciate everyone. enrollment treatment on development We in and advanced patients as and evaluating strides of Celcuity. Maria, VIKTORIA-X, clinical you, Thank afternoon, palbociclib second-line fulvestrant in We good advancing cancer without plus quarter. the gedatolisib III interest
schedule. enrolling trial prostate Our cancer castration-resistant also Phase evaluating Ib/II is patients on metastatic with
gedatolisib treatment a for our breast X to population phase expanded with designed as advanced patients And approvals, view, result VIKTORIA-X, a has that levels these for we estimate be blockbuster generate study late-stage patient when nearly III first-line If launch regulatory would efforts option ultimately in treated X we In patients gedatolisib further eligible the XXX,XXX cancer. HR+/HERX- each the initiated to evaluate potential programs to we programs of eligible gedatolisib. globally with of these to be revenue. cancer
over detectable patients that signed estimated We XXXX. first our was cohort. PIKXCA analysis analysis. X conduct this estimate primary and lack study's assumption the to May announced second we cohort the study half PIKXCA enrolled events and ago number time, trigger would enrollment mutations of turn, estimated XXXX. were the plans And the events wild-type PIKXCA of XX% that would At to in of reached the being wild-type cohort VIKTORIA-X threshold years that the this We used of patients by for required timing to in of primary be the for in to
the total variation enrollment And of we robust the within related shifted ago, than has this enrolled in study the wild-type is patients tumors believe of now over other on proportion will to relative overall population. the and wild-type And PIKXCA study's study lower be cohort enrolled normal the enrolled estimate sample the XX% X that PIKXCA estimate studies. while in original proportion, in the simply thus, while a our reins And We patients made the have rather result don't reported a we estimated. project originally remains within than this who of XX% years lower. but is shift track recently
wild-type for over XX% is complete. PIKXCA PIKXCA of completed, the proportion cohort enrollment lower Despite patients wild-type
of QX end wild-type of XXXX. quarter event reached the during the the enrollment primary between We to PIKXCA expect cohort as trigger the the will threshold sometime originally for we the target analysis We than and quarter QX the PIKXCA third end 'XX cohort wild-type be for the now reach rather forecast. fourth expect late
regarding patient triggered expect guidance unchanged, of the subgroup remains cohort to first for analysis this the we and during PIKXCA Our XXXX. mutant be half primary
recurs now initiate fulvestrant study. May. adjuvant We endocrine patients XX our as with a therapy. or announced months for will trial treatment evaluate of first-line while Turning gedatolisib this inhibitor Study to HR+/HERX- Phase breast our within whose VIKTORIA-X advanced clinical in plus cancer, III to plans this past completing disease receiving CDKX/X
endocrine disease Now these completing than a therapy. patients therapy more significantly adjuvant whose therapy their considered XX are to poor patients have after endocrine than have recurs resistant prognosis They sensitive disease. endocrine months
-- any Current understood results until last the inavolisib, standard PIXK INAVO-XXX inhibitors includes of of CDKX/X not December. efficacy the fulvestrant. of The regimens treatment therapy-resistant was patients offer combined resistant reported endocrine X patients, inhibitor, the Phase endocrine well for PIKXCA approved for with clinical these alpha therapy though, trial care III limited first-line study,
of with cancer. treatment therapy.
We the data As breast of X.X months. PFS only advanced same patients reported compare reported effective the advanced more with endocrine poorly to in were relapse months. part whose patients And efficacy standard PFS for to endocrine who for our palbociclib first And fulvestrant trial X.X therapies patients for cancer a disease from XX need for within clinical highlighting endocrine sensitive are median resistant their resistant the regimen, these preliminary PFS of care X for treatment the for evaluated are trial, those receive as median patients and was to was and this was Phase these Ib therapy, therapy. adjuvant significant years in And only results therapy that months first-line of the last to of the breast patients endocrine who as year gedatolisib patients, first-line median
the And results compare reported XX.X may favorably palbociclib response in you treatment treated results letrozole the and objective combination to who in survival, to and median As and plus the months population. recall, in XX%. for were with letrozole patients free palbociclib very this naive are endocrine-sensitive progressing rate gedatolisib with was these
patients in positive data. INAVO-XXX reported combined with study the endocrine-resistant and Additionally, evaluated that palbociclib inavolisib the fulvestrant
with PIKXCA these mutations not diabetic. patients had or Now the patients prediabetic were and tumors
represents the patient of only the XX% population. So total subgroup about endocrine-resistant
reported as However, pathway positive the role the driver relative PIKXCA of disease providing a plays critical evidence the treatment-naive to the further control, were of results in patients.
combination In well the choose is study, tested. run-in and to in inhibitor, either been with the Phase safety CDKX/X the evaluate investigators but be of or with patients of III yet run-in XX a combined profile And fulvestrant. of the Safe and and profile the dose gedatolisib clinically may will gedatolisib VIKTORIA-X confirmed fulvestrant completed for gedatolisib therefore, the ribociclib with palbociclib. Phase has palbociclib combined not described, before investigational will Safety safety study. enrolling approximately ribociclib gedatolisib III XX of with of ribociclib portion patients ribociclib
Blinded PFS ribo to the endpoints fulvestrant RECIST an each criteria will clinical per and of either progression-free for cohort PIKXCA endpoint trial or For on a to inhibitor are be mutation gedatolisib, selects investigator and arm And The status.
After on randomly assessed be be primary palbo. X.X treated Independent cohorts subject that this fulvestrant a survival, to study, palbociclib subject, for the either the by and patients one-to-one either as be approximately the primary the will treats evaluated with XXX Review. a independently. based assigned assigned X basis Central with subjects will assigned CDKX/X or be then ribociclib
was the during protocol. meeting And study designed we've first Studies received from type the also a discussed in on and reviewed quarter. recently with FDA FDA feedback then the just U.S. the
we can meeting, so As a selection part site and feasibility now D Type of on our focus activities.
across sites expect America, roughly We Europe, to the clinical in and expect second to XXXX. and the activate of Asia, Latin quarter first America North XXX patient enroll we
evaluating advanced cancer the with potential are United this the market diagnosed an increase to by U.S. $X estimate approval to therapy overlap to gedatolisib in our study, treat alone. patients VIKTORIA-X with population for endocrine the XX,XXX the does We States size each in breast that population up these resistant patient not of addressable billion. would Since XX,XXX patients year we're
in which financial the scale to efficacious we was of study the for proceed these that the decided developing III Given regimen a this, for therapeutic important net would we more this billion turn months possible estimate importance like been the now as so potential earlier of Ib/II needed financing, this raised quickly this our patients debt without value million we did a from have with cancer. patient February receptor gross population. metastatic now, present equity gedatolisib over we proceeds indication.
I'd able is Phase that's of evaluating balance we in revenue To opportunity, Phase combination from as on Study this with added initiate XX its the we and first stream this to $XXX dosed to to and we to to it $X do the patient when in to trial quarter efficacy sheet, our than strengthen and and this offerings. accomplish initiating By darolutamide, inhibitor year of prostate track. castration-resistant patients enrollment safety of an androgen trial
first expect XXXX. preliminary the data report to half in of continue We to
single the and models. vitro to Overall, these activity models. different pathway from of made. that I'm productive progress June, gedatolisib in tumor our pleased also multiple indicate who gedatolisib of published that AKT, in by was in research a inhibitors single-node than prostate over the types In lines.
And gedatolisib's compared node call models. in studies the inhibition turn describing recently similar August, Both at Molecular leading in finances. antitumor very very in and activity effects cancer PAM PAM the and PAM inducing results several in PIXK, And I'd pleased effective the in results node approved status activity Cancer review more PAM like compared of PAM vitro more published quarter. inhibitor Breast the exhibited PAM/PIXK/mTOR of various in like results in regardless busy now nodes potent of animal studies nonclinical pathway to We're Nature that's that to various our cytotoxic cell we breast published sets gedatolisib's inhibitors was or mutational a conducted will cancer single we vivo Vicky, it of demonstrated X inhibitors mTOR Oncology and studies journals.
